Amgen Inc.
General ticker "AMGN" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $156.1B (TTM average)
Amgen Inc. follows the US Stock Market performance with the rate: 42.8%.
Estimated limits based on current volatility of 1.6%: low 369.46$, high 380.92$
Factors to consider:
- Company included in S&P500 list
- Company included in NASDAQ-100 index
- Company pays dividends (irregularly): last record date 2026-02-13, amount 2.52$ (Y0.69%)
- Total employees count: 28000 as of 2024
- US accounted for 8.6% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Cybersecurity threats, Economic downturns and volatility, Manufacturing disruptions, Acquisition/divestiture risks, Climate change and natural disasters
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [272.09$, 384.99$]
- 2026-12-31 to 2027-12-31 estimated range: [311.35$, 431.20$]
Financial Metrics affecting the AMGN estimates:
- Negative: with PPE of 15.1 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 29.06 > 18.38
- Negative: Shareholder equity ratio, % of 9.56 <= 19.40
- Positive: 0.01 < Operating cash flow per share per price, % of 5.62
- Positive: Return on assets ratio (scaled to [-100,100]) of 7.84 > 6.11
- Positive: Interest expense per share per price, % of 1.55 <= 3.28
- Positive: 5.46 < Industry operating cash flow per share per price (median), % of 6.08
- Positive: Industry operating profit margin (median), % of 26.76 > 9.59
- Positive: Inventory ratio change, % of -2.82 <= -0.75
Short-term AMGN quotes
Relationship graph
Long-term AMGN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $28,190.00MM | $33,424.00MM | $36,741.00MM |
| Operating Expenses | $20,293.00MM | $26,166.00MM | $26,065.00MM |
| Operating Income | $7,897.00MM | $7,258.00MM | $10,676.00MM |
| Non-Operating Income | $-42.00MM | $-2,649.00MM | $-1,700.00MM |
| Interest Expense | $2,875.00MM | $3,155.00MM | $2,755.00MM |
| R&D Expense | $4,784.00MM | $5,964.00MM | $6,974.00MM |
| Income(Loss) | $7,855.00MM | $4,609.00MM | $8,976.00MM |
| Taxes | $1,138.00MM | $519.00MM | $1,265.00MM |
| Profit(Loss)* | $6,717.00MM | $4,090.00MM | $7,711.00MM |
| Stockholders Equity | $6,232.00MM | $5,877.00MM | $8,658.00MM |
| Inventory | $9,518.00MM | $6,998.00MM | $6,225.00MM |
| Assets | $97,154.00MM | $91,839.00MM | $90,586.00MM |
| Operating Cash Flow | $8,471.00MM | $11,490.00MM | $9,958.00MM |
| Capital expenditure | $1,112.00MM | $1,096.00MM | $1,858.00MM |
| Investing Cash Flow | $-26,204.00MM | $-1,046.00MM | $-1,943.00MM |
| Financing Cash Flow | $21,048.00MM | $-9,415.00MM | $-10,859.00MM |
| Earnings Per Share** | $12.56 | $7.56 | $14.33 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.